Infusion of forskolin, an adenylate cyclase activator, in concentrations (2 ,uM) that do not alter basal prostaglandin (PG) synthesis inhibit synthesis of PG elicited by isoproterenol in rabbit heart. This inhibitory action of forskolin appears to be dependent on cyclic AMP (cAMP). Bolus injection of forskolin (75 nmol), however, was found to stimulate PG synthesis in rabbit heart. The purpose of this study was to elucidate the mechanism of the stimulatory action of forskolin on PG synthesis (prostaglandin 12 measured as 6-ketoprostaglandin F,. in isolated perfused rabbit heart. Forskolin enhanced PG production in a dose-dependent manner. 1,9-Dideoxyforskolin, a forskolin analogue devoid of adenylate cyclase-stimulating activity, also enhanced PG synthesis. The cAMP analogue chlorophenylthio-cAMP failed to stimulate output of 6-keto-PGFi,a, although this agent produced dose-related changes in mechanical function in rabbit heart. Furthermore, the adenylate cyclase inhibitor (-)-N6-(Rphenylisopropyl)adenosine potentiated, whereas the phosphodiesterase inhibitor cilostamide attenuated, forskolin-stimulated PG production. (-)-N6-(R-Phenylisopropyl)adenosine and cilostamide had no effect on the mechanical actions of chlorophenylthio-cAMP, suggesting selectivity of these agents for adenylate cyclase and phosphodiesterase, respectively. 6-Keto-PGFW1 output elicited by forskolin was abolished by reduction of calcium in the perfusion fluid as well as by the calcium channel blocker diltiazem. The intracellular calcium antagonists TMB-8 and ryanodine also abolished forskolin-stimulated PG synthesis in rabbit heart. PG synthesis stimulated by 1,9-dideoxyforskolin was also prevented by reduced extracellular calcium, diltiazem, and ryanodine. The calmodulin antagonists trifluoperazine, W-7, and calmidazolium failed to significantly alter PG production in response to forskolin. These results indicate that forskolin-stimulated PG synthesis in rabbit heart is independent of cAMP and requires calcium from both extracellular and intracellular sources. (Circulation Research 1990;67:1247-1256 yclic AMP (cAMP) 
Infusion of forskolin, an adenylate cyclase activator, in concentrations (2 ,uM) that do not alter basal prostaglandin (PG) synthesis inhibit synthesis of PG elicited by isoproterenol in rabbit heart. This inhibitory action of forskolin appears to be dependent on cyclic AMP (cAMP). Bolus injection of forskolin (75 nmol), however, was found to stimulate PG synthesis in rabbit heart. The purpose of this study was to elucidate the mechanism of the stimulatory action of forskolin on PG synthesis (prostaglandin 12 measured as 6-ketoprostaglandin F,. in isolated perfused rabbit heart. Forskolin enhanced PG production in a dose-dependent manner. 1,9-Dideoxyforskolin, a forskolin analogue devoid of adenylate cyclase-stimulating activity, also enhanced PG synthesis. The cAMP analogue chlorophenylthio-cAMP failed to stimulate output of 6-keto-PGFi,a, although this agent produced dose-related changes in mechanical function in rabbit heart. Furthermore, the adenylate cyclase inhibitor (-)-N6-(Rphenylisopropyl)adenosine potentiated, whereas the phosphodiesterase inhibitor cilostamide attenuated, forskolin-stimulated PG production. (-)-N6-(R-Phenylisopropyl)adenosine and cilostamide had no effect on the mechanical actions of chlorophenylthio-cAMP, suggesting selectivity of these agents for adenylate cyclase and phosphodiesterase, respectively. 6-Keto-PGFW1 output elicited by forskolin was abolished by reduction of calcium in the perfusion fluid as well as by the calcium channel blocker diltiazem. The intracellular calcium antagonists TMB-8 and ryanodine also abolished forskolin-stimulated PG synthesis in rabbit heart. PG synthesis stimulated by 1,9-dideoxyforskolin was also prevented by reduced extracellular calcium, diltiazem, and ryanodine. The calmodulin antagonists trifluoperazine, W-7, and calmidazolium failed to significantly alter PG production in response to forskolin. These results indicate that forskolin-stimulated PG synthesis in rabbit heart is independent of cAMP and requires calcium from both extracellular and intracellular sources. (Circulation Research 1990; 67:1247 -1256 yclic AMP (cAMP) has been shown to influ-C ence prostaglandin (PG) synthesis in several tissues. For example, cAMP attenuates PG synthesis in collecting tubule cells,' MDCK cells,2 and platelets.3 However, PG synthesis was enhanced by increasing levels of cAMP in human decidua and amnion cells.4 cAMP analogues have also been pyl)adenosine (PIA) enhanced, isoproterenol-stimulated PG synthesis in rabbit heart suggest that cAMP acts as a physiological modulator of PG synthesis elicited by activation of ,B-adrenergic receptors.12 However, our observation that forskolin, given as bolus injections of 75 nmol, stimulated PG synthesis raises the possibility that forskolin acting through cAMP might exert a biphasic effect on cardiac PG synthesis, depending on the concentration, or that forskolin stimulates PG synthesis by a mechanism independent of cAMP. The purpose of the present study was to elucidate the mechanism of forskolinstimulated PG synthesis in rabbit heart. The effect of AC and PDE inhibitors, alterations in extracellular calcium concentration, extracellular and intracellular calcium antagonists, and calmodulin inhibitors on forskolin-stimulated PG synthesis was investigated. In addition, the effects of a cAMP analogue, cptcAMP, and 1,9-dideoxyforskolin, a forskolin analogue devoid of AC-stimulating activity,13 on cardiac PG synthesis were also determined.
Materials and Methods Isolated Heart Preparation
All experiments were performed in hearts isolated from male New Zealand White rabbits (Myrtles Rabbitry, Thompson's Station, Tenn.) weighing 1-2 kg. The rabbits were maintained on normal laboratory chow and given water ad libitum. Animals were anesthetized with sodium pentobarbital administered intravenously, and a midline abdominal incision was made for injection of heparin (1,000 units/kg) into the vena cava. The thorax was opened, and the heart was rapidly removed and placed in Krebs-Henseleit (K-H) buffer fluid-filled balloon catheter inserted into the left ventricle through a small incision in the apex. The maximal first derivative of left ventricular pressure (LV dP/dt), which is indicative of myocardial contractile force, was determined from the ventricular pressure signal by using a differentiator (model 7P20, Grass Instruments Co., Quincy, Mass.). Heart rate (HR) was determined using an EKG tachograph (model 7P4F, Grass) triggered by ventricular contraction. These mechanical parameters were recorded with a Grass polygraph (model 7D).
Experimental Protocol
Hearts were allowed to stabilize for a 25-minute period before initiation of any experimental interventions. Perfusate samples were collected immediately before and after injections of forskolin or 1,9-dideoxyforskolin for determination of basal and stimulated levels of prostaglandin 12 output. Prostaglandin '2 was measured as the stable hydrolysis product 6-ketoprostaglandin F1, ) . In the experiments with the cAMP analogue cpt-cAMP, samples were obtained immediately before and at intervals of 1 minute during the infusion of this agent. Intervals of 15 minutes separated injections of forskolin or infusion of cpt-cAMP to allow recovery of mechanical and metabolic parameters. Perfusate samples were stored at -20°C until radioimmunoassay of 6-ketoPGFl,.
Protocol 1. The first series of experiments was performed to determine the effects of forskolin, cpt-cAMP, and 1,9-dideoxyforskolin on 6-ketoPGF1a output and mechanical function in rabbit heart. Forskolin was injected as a bolus at 2.5, 25, 75, and 250 nmol in a volume of 100 gl. Injections of these different concentrations of forskolin were given in separate hearts. The effect of the forskolin analogue 1,9-dideoxyforskolin, which lacks AC-stimulating activity,13 on 6-keto-PGFl, output from rabbit heart was also determined. 1,9-Dideoxyforskolin was injected as a 100-1l bolus in a dose of 250 or 660 nmol. Perfusate samples were collected for 1 minute immediately before and for two 1-minute periods immediately after each injection of forskolin or 1,9-dideoxyforskolin. Because forskolin and the 1,9-dideoxy analogue were dissolved in dimethyl sulfoxide, the effect of this solvent on PG output was examined. The peak changes of Pp, HR, and LV dP/dt in response to increasing concentrations of forskolin or to 1,9-dideoxyforskolin were also determined.
cpt-cAMP was administered in concentrations of 100, 200, and 300 ,uM in separate hearts. After the stabiliziation period, the perfusion fluid was switched to a second reservoir of K-H buffer containing cptcAMP at the desired concentration. Perfusate samples were collected for 1 minute immediately before and at intervals of 1 minute during the 5-minute perfusion with cpt-cAMP for measurement of 6-keto-PGFia. Peak changes of Pp, HR, and LV dP/dt in response to cpt-cAMP were also ascertained.
Protocol 2. This series of experiments was conducted to determine the effects of AC and PDE inhibitors on forskolin-stimulated output of 6-keto-PGF1,. Forskolin (75 nmol) was injected after the stabilization period and 15 minutes later in the presence of the adenosine analogue AC antagonist PIA, the PDE inhibitor cilostamide [N-cyclohexyl-Nmethyl-4-(1,2-dihydro-2-oxo-6-quinolyloxy)butyramide], or normal K-H buffer. PIA was infused (0.1 ml/min) into the perfusion line with a syringe pump (model 341A, Sage Instruments, Cambridge, Mass.) to achieve a final concentration of 1 ,M. Infusion of PIA was started 5 minutes before and continued through the second injection of forskolin. In the experiments with PDE inhibition, hearts were perfused with K-H buffer containing cilostamide (5 ,uM) beginning 5 minutes before and continuing through the second injection of forskolin. Perfusate samples were collected for 1 minute immediately before and for two 1-minute periods immediately after each injection of forskolin for measurement of 6-ketoPGFia output. The effects of PIA and cilostamide on forskolin-stimulated changes of Pp, HR, and LV dP/dt were also determined.
In other experiments, the effects of PIA and cilostamide on cpt-cAMP-induced changes in mechanical function were investigated. cpt-cAMP (250 ,M) was infused in the absence, and 15 minutes later in the presence, of PIA and cilostamide. Infusion of PIA (1 ,uM) or perfusion with K-H buffer containing cilostamide (5 ,lM) was started 5 minutes before and continued through the second infusion of cpt-cAMP.
Protocol 3. This series of experiments was performed to determine the effects of reduction of extracellular calcium, calcium channel blockade, intracellular calcium antagonists, and calmodulin inhibitors on forskolin-and 1,9-dideoxyforskolin-stimulated 6- keto-PGFla output. Forskolin was administered during perfusion with normal K-H buffer and 15 minutes later during perfusion with K-H buffer containing either 0.5 or 0 mM calcium, the calcium channel blocker diltiazem (23 ,M) , the intracellular calcium antagonists TMB-8 (22 ,M) or ryanodine (1.6 MM), or the calmodulin inhibitors trifluoperazine (50 ,uM), calmidazolium (5 pgM), or W-7 (1 pM). Perfusion of hearts with reduced calcium K-H buffer or buffer containing one of the various calcium or calmodulin inhibitors was initiated 10 minutes before and continued through the second injection of forskolin. Perfusate sample collection was identical to that described in protocol 2. Injections of 1,9-dideoxyforskolin in the absence and presence of reduced perfusate calcium (0.5 mM), diltiazem (23 ,uM) , or ryanodine (1.6 gM)
were given in separate hearts. Perfusion with buffer containing reduced calcium, diltiazem, or ryanodine was initiated 10 minutes before injection of 1,9-dideoxyforskolin. Samples were collected immediately before and for two 1-minute periods immediately after injection of this agent.
Assay of 6-Keto-PGFI,
The perfusate concentration of 6-keto-PGFia, the stable hydrolysis product of prostaglandin 12, was determined by radioimmunoassay. Aliquots (100 ml each) of the perfusate samples were mixed with 2,000-3,000 cpm of [3H]-6-keto-PGFia tracer and the appropriate concentration of antibody. The antibody to 6-keto-PGFia was obtained from Dr. Charles Leffler, Department of Physiology and Biophysics, University of Tennessee, Memphis. The tracer and antibody were prepared in a buffer solution consisting of (grams/liter) NaN3 1.0, NaCl 9.0, KH2PO4 6.8, K2HPO4 26.1, and gelatin 2.0. 6-Keto-PGFla standards (1-1,000 pg) were prepared in K-H buffer. The tubes containing the assay mixture were vortexed and stored overnight at 40 C. Unbound tracer was removed by the addition of dextran-coated charcoal to the tubes. After centrifugation, the supernatant was decanted into vials containing 5 ml counting cocktail, and radioactivity was determined by liquid scintillation spectroscopy. Cross-reactivity of the 6-ketoPGFia antibody was less than 0.1% with thromboxane B2, 13,14-dihydro-15-ketoprostaglandin E2, and prostaglandin 12, and less than 0.5% with prostaglandin E2 and prostaglandin F2a.
Drugs
The following drugs used in this study were purchased: forskolin and 1,9-dideoxyforskolin (Calbiochem Corp., San Diego), cpt-cAMP (Sigma Chemical Co., St. Louis), PIA (Boehringer Mannheim Biochemicals, Indianapolis), TMB-8 (Aldrich Chemical Co., Inc., Milwaukee), W-7 (Rikaken Co., Nagoya, Japan), and calmidazolium R24571 (Janssen Pharmaceutical, Beerse, Belgium). The drugs obtained gratis were cilostamide (Otsuka Pharmaceutical Co., Ltd., Higashi-ku, Osaka, Japan), diltiazem (Marion Laboratories, Kansas City, Mo.), ryanodine (Merck Sharp & Dohme, West Point, Pa.), and trifluoperazine (Smith Kline & French Laboratories, Philadelphia).
Stock solutions (1 mg/ml) of forskolin, 1,9-dideoxyforskolin, and PIA were prepared in dimethyl sulfoxide and stored at -20°C. These solutions were diluted with K-H buffer on the day of the experiment to achieve the appropriate concentration for injection or infusion. cpt-cAMP, diltiazem, TMB-8, ryanodine, trifluoperazine, W-7, and calmidazolium were added directly in K-H buffer to obtain the desired final concentration. Cilostamide was initially dissolved in absolute ethanol at a concentration of 1 mg/ml and the appropriate volume was added to K-H buffer to achieve the final concentration.
Statistical Analysis
The data are presented as the mean±SEM change from basal values of 6-keto-PGFl, output and mechanical parameters. Comparisons were made using paired and unpaired t tests. Differences were considered significant at p<0.05.
Results
Effects of Forskolin, cpt-cAMP, and 1,9-Dideoxyforskolin on 6-Keto-PGF,0
Output and Mechanical Function of Rabbit Heart
Forskolin enhanced output of 6-keto-PGF1, in a dose-dependent manner with significant increases occurring at 75-and 250 -nmol doses but not at lower doses of 2.5 and 25 nmol (Figure 1 ). 1,9-Dideoxyforskolin (250 nmol) was also found to stimulate production of 6-keto-PGFl0 (Figure 1 2.18±0.4 ng/min, versus stimulated, 4.49±0.6 ng/ min;p<0.025, n=4). A 100-,ul injection of dimethyl sulfoxide, the vehicle for forskolin and 1,9-dideoxyforskolin, had no effect on output of 6-keto-PGFl, (2.1±0.3 ng/min before versus 2.6±0.6 ng/min after). In contrast to the effect of forskolin, cpt-cAMP had no effect on PG production at concentrations of 100-300 ,uM at any point in the 5-minute perfusion ( Figure 1 ).
Increasing concentrations of forskolin enhanced levels of HR and LV dP/dt in a dose-dependent manner ( Figure 2 ). The Pp response to forskolin was somewhat variable. The 25-nmol dose of forskolin resulted in the largest reduction of Pp, but the basal Pp was also highest in this group. In the groups with similar basal levels of Pp, forskolin produced a dose-dependent decrease in Pp. 1,9-Dideoxyforskolin (250 nmol) resulted in a decrease in LV dP/dt, whereas HR and Pp were unaltered ( Figure 2 ). Higher doses (660 nmol) of this agent also produced similar changes in mechanical function. The mechanical actions of cpt-cAMP are also shown in Figure 2 . The cpt-cAMP-induced changes of mechanical function developed gradually and reached maximum levels by the fourth or fifth minute of perfusion. 15 -min intervals produced similar increases of 6-keto-PGFia, production ( Figure 3 ). The AC inhibitor PIA enhanced by twofold the output of 6-ketoPGFlia elicited by forskolin, whereas the PDE inhibitor cilostamide reduced by 50% forskolin-stimulated output of 6-keto-PGFia (Figure 3) . Basal values of 6-keto-PGFi,a output were not altered in the presence of PIA or cilostamide.
The effects of PIA and cilostamide on the mechanical actions of forskolin are shown in Figure 4 . Two repeated injections of forskolin (75 nmol) produced virtually identical effects on Pp, HR, and LV dP/dt. In the presence of PIA, basal levels of Pp, HR, and LV dP/dt were reduced, and forskolin-induced changes of these parameters were attenuated. Basal levels of Pp tended to decrease, and HR increased by 43 beats/min in the presence of cilostamide, while LV dP/dt was not altered. Cilostamide tended to reduce the HR and enhance the LV dP/dt responses to forskolin, but the changes did not reach significance. The Pp response to forskolin was unaltered in the presence of cilostamide.
The effects of the AC and PDE inhibitors on the mechanical actions of cpt-cAMP were also investigated, and the results are shown in Figure 5 . Two repeated 5-minute infusions of cpt-cAMP (250 ,uM) given at 15-minute intervals resulted in identical effects on Pp, HR, and LV dP/dt. PIA (1 ,uM) Reduction of calcium from 2.5 to 0.5 or 0 mM or addition of diltiazem (23 ,uM) to the perfusion fluid had no effect on basal levels of 6-keto-PGFl, output. Forskolin-stimulated 6-keto-PGFl, production was completely abolished during perfusion with K-H buffer containing either 0.5 or 0 mM calcium ( Figure  6 ). Similar results were obtained when hearts were perfused with K-H buffer containing diltiazem (Figure 6 ). Reduction of perfusate calcium to 0.5 mM or addition of diltiazem (23 ,uM) to the perfusate completely prevented output of 6-keto-PGFia elicited by 1,9-dideoxyforskolin ( Figure 7 ). Hearts ceased to beat when exposed to 0 mM calcium or diltiazem. In the presence of 0.5 mM calcium, Pp was unaltered, whereas HR decreased from 148+7 to 134+±5 beats/ min (p.<0.05) and LV dP/dt decreased from 1,083+89 to 342±79 mm Hg/sec (p<O.OO1). Lower- ing the calcium concentration to 0.5 mM reduced the forskolin-stimulated increases in HR (120±+8 versus 75±+11 beats/min;p<0.05) and LV dP/dt (1,254+263 versus 225+±65 mm Hg/sec; p<O.O1).
Perfusion of hearts with K-H buffer containing TMB-8 (22 gM) reduced basal levels of 6-ketoPGF1a and completely prevented stimulation of 6-keto-PGFia production by forskolin (Figure 8 ). In a second group of hearts, the effect of another intracellular calcium antagonist, ryanodine, was investigated. In contrast to TMB-8, ryanodine did not alter basal values of 6-keto-PGFia output, but forskolinstimulated production of this PG was abolished (Figure 8) . Ryanodine also was found to prevent 1,9-dideoxyforskolin-stimulated production of 6-ketoPGF1a ( Figure 7 ). forskolin, but the differences were not significant ( Figure 9 ). None of the three agents altered basal levels of PG production. A significant increase in 6-KETO-PGFIa output over basal levels is shown (tp<0.05).
trifluoperazine and W-7 attenuated the forskolinstimulated increase of LV dP/dt. Discussion Our previous study indicates that cAMP acts as a negative feedback regulator of ,B-adrenergic receptor-stimulated cardiac PG synthesis.12 Supporting this view, we demonstrated that cpt-cAMP and PDE inhibitors attenuated, and the AC antagonist PIA potentiated, PG synthesis elicited by the f3-adrenergic receptor agonist isoproterenol in rabbit heart.12 Moreover, infusion of forskolin (2 ,uM), which directly activates AC7 and enhances cAMP accumulation in rabbit papillary muscle,14 inhibited isoproterenol-induced PG synthesis without altering basal output of PGs from rabbit heart.12 However, bolus injections of forskolin (75 nmol) enhanced basal cardiac PG synthesis. Forskolin has also been shown to stimulate PG synthesis in human amnion and decidua cells, and this effect appeared to be dependent on cAMP. 4 Satoh et al15 showed that low concentrations (10-100 nM) of forskolin stimulated PG synthesis in dog renal artery, apparently by a cAMP-independent mechanism, whereas higher concentrations (10-100 ,uM) failed to alter PG synthesis. The present study, which was undertaken to elucidate the mechanism of forskolin-stimulated PG synthesis in isolated rabbit heart, indicates that forskolin promotes cardiac PG synthesis by a mechanism un- Cardiac PG synthesis elicited by forskolin could be consequential to the positive inotropic or chronotropic effects or the coronary vasodilation produced by this agent. However, forskolin-stimulated PG synthesis appears to be unrelated to mechanical function of the heart for the following reasons. cpt-cAMP produced a positive inotropic effect and reduced Pp without altering PG synthesis. Moreover, 1,9-dideoxyforskolin augmented PG production while eliciting a negative inotropic effect. Increasing HR by electrical pacing also failed to alter PG synthesis in rabbit heart. 24 An important finding in the present study was that PG synthesis induced by forskolin and 1,9-dideoxyforskolin was inhibited by reduction or depletion of extracellular calcium. This observation and our finding that the calcium channel blocker diltiazem also inhibited PG production elicited by forskolin and its dideoxy analogue suggest that these agents promote cardiac PG synthesis by increasing influx of calcium through voltage-dependent channels. Forskolin has been reported to increase intracellular calcium concentrations in pituitary cells. 25 The ability of forskolin to stimulate voltage-dependent calcium channels independently of cAMP production has recently been demonstrated in bovine adrenal fasciculata cells. 26 Entry of calcium into cardiac cells could act directly or trigger calcium release from intracellular storage sites,27 which then activates one or more of the lipases involved in release of arachidonic acid. Our demonstration that two structurally different intracellular calcium antagonists, TMB-8w-and ryanodine,29 abolished 6-keto-PGFl,, output elicited by forskolin suggest that mobilization of intracellular calcium is involved in PG synthesis induced by this agent. PG synthesis stimulated by 1,9-dideoxyforskolin was also found to be inhibited by ryanodine. These findings suggest that forskolin and its dideoxy analogue share a common mechanism of action to promote cardiac PG synthesis. From these observations, it follows that forskolin and 1,9-dideoxyforskolin enhance influx of extracellular calcium into cardiac cells, which in turn triggers calcium release from intracellular storage sites leading to activation of one or more lipases that release arachidonic acid from tissue phospholipids. 35 In the present study, three structurally distinct calmodulin inhibitors failed to significantly attenuate forskolin-stimulated cardiac PG synthesis, although there was a tendency toward inhibition of this response. These findings do not support a role of calmodulin in the mechanism underlying prostaglandin synthesis induced by forskolin; however, a role of calmodulin cannot be completely ruled out. PG synthesis induced by isoproterenol in rabbit heart is also dependent on calcium but does not require calmodulin. 30 However, in human amnion and decidua cells, calmodulin appears to be involved in prostaglandin synthesis. 4 The exact mechanism by which forskolin promotes influx of calcium through voltage-dependent channels in the rabbit heart is not known. Most of the biological actions of forskolin are thought to be mediated by cAMP, although several actions of this agent have been reported to be independent of cAMP. For example, forskolin-induced acetylcholine receptor desensitization36'37 and inhibition of voltage-dependent potassium channels38 are not mediated by cAMP but rather appear to be related to the hydrophobic properties of this agent.3637 Although the mechanism of forskolin-induced calcium mobilization remains to be elucidated, it may be speculated that forskolin and 1,9-dideoxyforskolin promote calcium entry into heart cells by a hydrophobic interaction at or near calcium channels.
The precise site and mechanism by which increased cellular calcium activates a lipase involved in arachidonic acid liberation remains to be determined. Because conversion of exogenous arachidonic acid to 6-keto-PGF,a occurs predominantly in the coronary vasculature in the perfused rabbit heart,39 it is possible that the site of action of forskolin is in the coronary vasculature. However, in view of the demonstration that isolated cardiac myocytes are capable of synthesizing PG,40 we cannot rule out the possibility that forskolin and its dideoxy analogue also stimulate PG synthesis in myocytes.
In conclusion, this study indicates that forskolin stimulates cardiac PG synthesis by a mechanism independent of cAMP. In fact, cAMP generated by forskolin appears to inhibit PG production elicited by this agent. Forskolin-stimulated PG synthesis in rabbit heart is most likely due to increased influx of extracellular calcium into cardiac cells, which by mobilizing intracellular calcium activates one or more lipases to release arachidonic acid for PG synthesis.
